双鹭药业：公司DT678片目前已进入临床二期，从一期结果看其疗效优于氯吡格雷

Core Viewpoint - The company has developed DT678 tablets, a globally innovative drug for anti-platelet aggregation, which is currently in Phase II clinical trials and shows superior efficacy compared to Clopidogrel with fewer side effects [1][3]. Group 1 - DT678 tablets are a co-development between the company and DT Company, which is partially owned by the University of Michigan, with the company holding a 30% stake in DT Company [1][3]. - The company possesses exclusive rights for the development and use of the patented compound in China [1][3]. - Preliminary results from Phase I trials indicate that DT678 has over 20 times the efficacy of Clopidogrel, with advantages such as rapid onset, fewer side effects, and greater stability [3].